We’ve known for decades that a prematurely short cervix puts pregnant women at high risk for a potentially tragic preterm birth. There’s finally an evidence-based treatment which cuts that risk nearly in half. The CerviLenz device makes cervical length measurements easy for you and your patients at any prenatal visit.
ACOG now joins SMFM in recommending vaginal progesterone treatment to help prevent preterm
birth for asymptomatic singletons with a short cervix.
It’s time to add cervical length measurements to the list of routine screening tests during pregnancy.
Prematurity continues to be the biggest challenge in obstetrics. About half of all preterm births happen in pregnancies considered low risk. A shortening cervix, which can be caused by a progesterone deficiency, is a sign that the pregnancy is at high risk for preterm birth. With Level 1 evidence that vaginal progesterone treatment can prevent early delivery in these pregnancies, and improve infant outcomes, adding a simple screen for cervical length to routine care of singletons makes sense.
We are here to help. A simple cervical length measurement with the CerviLenz device during a regular office visit can put everyone’s mind at ease. Most pregnant women have a long cervix and won’t need further assessment. But if her CerviLenz measurement is short, your next step is a transvaginal ultrasound exam. Either way, she knows she’s getting the care she needs.
Cost effective innovation – the CerviLenz device helps you advance care for your pregnant patients.
With immediate and actionable results, the CerviLenz procedure gives you a reliable cervical length measurement at the point of care. Read on to learn how the CerviLenz device is used and click here to find our training resources.
There is Level 1 evidence that vaginal progesterone treatment can prevent preterm birth for pregnant women diagnosed with a prematurely short cervix. It also improves infant outcomes. That’s why ACOG published a new Practice Bulletin and SMFM published a new Clinical Guideline. Want to see the evidence for yourself? Read the NIH study by Dr. Hassan et al. and the meta-analysis by Dr. Romero et al.
Stuart Campbell, MD said it best in an editorial accompanying publication of the NIH study, “Doing nothing is no longer an option.” We can’t afford to wait any longer to add cervical length screening to routine prenatal care of singletons to find patients who need intervention.
CerviLenz makes it easy to put this prematurity prevention strategy into practice today.